NCT05980000 (Rambro2) is a Phase 2 clinical trial of Ramucirumab in Recurrent Head and Neck Cancer, sponsored by Washington University School of Medicine.

Who is sponsoring NCT05980000?

NCT05980000 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT05980000?

Interventions in NCT05980000: Ramucirumab, Pembrolizumab.

What condition does NCT05980000 study?

NCT05980000 studies Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC.

Is NCT05980000 still recruiting?

NCT05980000 is currently active, enrolled. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT05980000: Rambro2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Active, enrolled Phase 2 Last updated 31 March 2026

What this trial tests

Phase 2 trial testing Ramucirumab in Recurrent Head and Neck Cancer in 37 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 October 2023

Primary endpoint
30 June 2027

30 June 2030

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	27 October 2023
Primary completion	30 June 2027
Estimated completion	30 June 2030
Sites	1 location across United States

Drugs / interventions tested

Ramucirumab (RAMUCIRUMAB) — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Recurrent Head and Neck Cancer — all drugs for Recurrent Head and Neck Cancer →
Recurrent Head and Neck Squamous Cell Carcinoma — all drugs for Recurrent Head and Neck Squamous Cell Carcinoma →
Recurrent Head and Neck Carcinoma — all drugs for Recurrent Head and Neck Carcinoma →
Metastatic Head-and-neck Squamous-cell Carcinoma — all drugs for Metastatic Head-and-neck Squamous-cell Carcinoma →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Recurrent Head and Neck Cancer or Recurrent Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 study investigating the efficacy of ramucirumab in combination with pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy.
Fan Y, Feng R, Zhang X, Wang ZL, et al · · 2024 · cited 22× · PMID 39220863 · DOI 10.1016/j.apsb.2024.04.006
Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas.
Gauss C, Stone LD, Ghafouri M, Quan D, et al · · 2024 · cited 10× · PMID 38920648 · DOI 10.3390/cells13121018
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.
Adkins D, Ley JC, Liu J, Oppelt P. · · 2024 · cited 9× · PMID 38851207 · DOI 10.1016/s1470-2045(24)00204-3
Systemic therapy for laryngeal carcinoma.
Fuereder T, Kocher F, Vermorken JB. · · 2025 · cited 4× · PMID 40104492 · DOI 10.3389/fonc.2025.1541385

Verify or expand the search:

Other trials of Ramucirumab

Trials testing the same drug.

NCT06996782 — A Platform Study in Non-Small Cell Lung Cancer (NSCLC) · Phase 1, PHASE2 · recruiting
NCT06675136 — Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal · Phase 1 · recruiting
NCT07098338 — A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT06616584 — Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had · Phase 2, PHASE3 · recruiting
NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Recurrent Head and Neck Cancer

Currently open trials in the same condition.

NCT06869473 — Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R · Phase 2 · recruiting
NCT06239220 — PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC · Phase 2 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05980000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05980000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing